Clinical Trials on Mammographic Breast Density in Australia

Total 508 results

Sanofi

Completed

Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)

Breast Cancer | Prostatic Neoplasms

Australia
Sanofi

Completed

BIG 02/98 Docetaxel - Breast Cancer

Breast Neoplasms

Spain, Italy, Australia, Czech Republic, Germany, Hungary, Ireland, Israel, New Zealand, Portugal, Slovenia, Slovakia, Austria, Sweden, United Kingdom, Belgium, Brazil, Chile, Denmark, South Africa, Switzerland
Iksuda Therapeutics Ltd.

Recruiting

IKS014 in Advanced Solid Tumors That Express HER2

Breast Cancer | Gastric Cancer | Gastroesophageal-junction Cancer

Australia
AstraZeneca

Completed

Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC) (FIONA)

Breast Cancer

Austria
EMD Serono

Terminated

STRIDE - STimulating Immune Response In aDvanced brEast Cancer (STRIDE)

Breast Cancer

Czech Republic, Korea, Republic of, Russian Federation, South Africa, Germany, Slovakia, Austria, United States, Belgium, Poland, Israel, Australia
AstraZeneca

Completed

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

Advanced Breast Cancer

United States, Australia, Brazil
AstraZeneca
Parexel

Completed

Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer

Metastatic Breast Cancer

Taiwan, Hong Kong, Australia, Singapore, Korea, Republic of, Brazil
Gilead Sciences

Active, not recruiting

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)

Triple-Negative Breast Cancer

United States, United Kingdom, Australia, Hong Kong, Korea, Republic of, Taiwan
Motiva USA LLC

Recruiting

Long-Term Effectiveness of the Motiva Implants® Round and Round Ergonomix (MIRO)

Breast Augmentation

Australia, Costa Rica, Italy, Spain
Fusion Pharmaceuticals Inc.

Recruiting

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer | Uveal Melanoma | Adrenocortical Carcinoma | Advanced Solid Tumours | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Canada
University of Erlangen-Nürnberg Medical School

Unknown

APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer

Breast Cancer

Austria, Germany, Hungary, Poland, Spain
Genentech, Inc.

Completed

A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

Breast Cancer

United States, Spain, Belgium, Australia, United Kingdom
Genentech, Inc.

Terminated

A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy (HydranGea)

Breast Cancer

United States, Spain, United Kingdom, Germany, Korea, Republic of, Australia
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Breast Cancer

Italy, Korea, Republic of, Spain, Taiwan, United Kingdom, Brazil, Russian Federation, Thailand, Israel, Turkey, Austria, Canada, Poland, Sweden, Australia, Peru, Switzerland, Mexico
AstraZeneca
Daiichi Sankyo, Inc.

Completed

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Breast Cancer

United States, Germany, Italy, Korea, Republic of, United Kingdom, Portugal, Australia, Japan, Canada, France
Novartis Pharmaceuticals

Completed

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (EVEREXES)

Post Menopausal Breast Cancer

Taiwan, Malaysia, Turkey, Australia, Korea, Republic of, Thailand, Jordan, India, Vietnam, Morocco, Tunisia, Indonesia, South Africa
Hoffmann-La Roche

Completed

A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours

Breast Cancer, Colorectal Cancer

New Zealand, Australia, United Kingdom
Genentech, Inc.

Active, not recruiting

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Breast Cancer

United States, Spain, Korea, Republic of, Australia, United Kingdom
Instituto de Investigacion Sanitaria La Fe
Karolinska Institutet; Medical University of Vienna; Ain Shams University; Medical... and other collaborators

Recruiting

Clinical Validation of Radiomics Artificial Intelligence: Application to Breast Cancer Treatment Planning (RADIOVAL)

Breast Cancer

Austria, Sweden, Turkey, Argentina, Croatia, Egypt, Poland, Spain
ModernaTX, Inc.
AstraZeneca

Active, not recruiting

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma

United States, Israel, Australia
Hoffmann-La Roche

Recruiting

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Breast Cancer

Korea, Republic of, United States, Israel, Denmark, Argentina, Mexico, Brazil, Germany, Peru, Poland, Spain, Taiwan, South Africa, Czechia, Australia
Institut de Recherches Internationales Servier
Breast International Group

Completed

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer (FINESSE)

Breast Cancer

United Kingdom, Italy, France, Belgium, Australia, Canada, Germany, Hungary, Spain
Amgen

Completed

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Locally Recurrent and Metastatic Breast Cancer

United States, United Kingdom, Denmark, Poland, Belgium, Hungary, Spain, Austria, France, Australia, Netherlands, Finland, India
Zhejiang Medicine Co., Ltd.
Ambrx, Inc.

Terminated

A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

Stomach Neoplasms | Breast Neoplasms

Australia, New Zealand
GlaxoSmithKline

Terminated

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Neoplasms

United States, Korea, Republic of, Canada, Spain, Australia, United Kingdom, France
Ambrx, Inc.

Completed

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Breast Neoplasms | Solid Tumors | Gastric Neoplasm

United States, Australia
GlaxoSmithKline

Completed

A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer

Neoplasms, Breast

Belgium, United States, Australia, France, Italy
Canadian Cancer Trials Group
Hoffmann-La Roche

Active, not recruiting

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)

Breast Cancer

Australia, Canada, New Zealand
Celgene

Completed

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (tnAcity)

Breast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...

United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
University Hospital, Basel, Switzerland
Swiss National Science Foundation

Active, not recruiting

Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy OPBC-02PREPEC (OPBC-02PREPEC)

Breast Reconstruction | Implant-Based Breast Reconstruction (IBBR)

Austria, Sweden, Germany, Hungary, Switzerland, United States, Italy
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer (VERITAC-3)

Breast Cancer

United States, China, Spain, Hungary, Japan, Australia, Brazil, Italy, Slovakia, Switzerland
Genentech, Inc.

Completed

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

United States, Korea, Republic of, Australia, Austria, Czechia, United Kingdom, Belgium, Spain
Hoffmann-La Roche

Terminated

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Breast Cancer

Israel, Italy, Spain, United States, Belgium, Czechia, Australia, United Kingdom, Korea, Republic of, Romania, France, Taiwan, Latvia
Novartis Pharmaceuticals

Completed

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer

Breast Cancer

Spain, United Kingdom, Taiwan, Australia, Russian Federation, Germany, Korea, Republic of, Ireland, United States, Italy, Brazil, Czech Republic
Hoffmann-La Roche

Completed

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031)

Triple-negative Breast Cancer

United States, Korea, Republic of, Canada, United Kingdom, Belgium, Brazil, Germany, Taiwan, Australia, Japan, Spain, Poland, Italy
AVEO Pharmaceuticals, Inc.
Astellas Pharma Inc

Terminated

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (BATON-BC)

Triple Negative Breast Cancer

Germany, Taiwan, Spain, Ukraine, Australia, Korea, Republic of, Canada, United States, Italy, Bahamas
Bayer
Onyx Therapeutics, Inc.

Completed

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Breast Cancer

Spain, Ireland, Japan, Russian Federation, United States, Australia, Austria, Czechia, Belgium, China, Germany, Hungary, Israel, South Africa, United Kingdom, France, Greece, Puerto Rico, Italy, Canada, Poland, Sweden, Argentina
AstraZeneca

Active, not recruiting

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer (OlympiaN)

Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Germany, Austria, Israel, Australia
Hoffmann-La Roche

Completed

A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer

Breast Cancer

Italy, Spain, China, Taiwan, Russian Federation, Canada, Germany, Austria, Hungary, Belgium, Australia, Brazil, Mexico, Poland, Panama
Pfizer

Terminated

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

Advanced Breast Cancer

United States, Hungary, Spain, Belgium, China, Hong Kong, Australia, Poland, Canada, India, South Africa
Eli Lilly and Company

Completed

A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients

Breast Cancer

Austria, Czech Republic, Hungary, Poland, Romania, Russian Federation
Austrian Breast & Colorectal Cancer Study Group
AstraZeneca; Novartis Pharmaceuticals

Completed

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

Breast Cancer

Austria, Germany
Multitude Therapeutics Inc.
Tigermed Consulting Co., Ltd

Recruiting

AMT-151 in Patients With Selected Advanced Solid Tumours

Ovarian Cancer | Ovarian Epithelial Cancer | Lung Adenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Endometrial Cancer | Advanced Cancer | Ovarian Clear Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial... and other conditions

China, Australia
ETOP IBCSG Partners Foundation

Completed

Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98

Breast Cancer | Fatigue | Cognitive/Functional Effects | Psychosocial Effects of Cancer and Its Treatment

Belgium, Switzerland, United Kingdom, Australia, Italy, New Zealand
R-Pharm

Completed

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Metastatic Breast Cancer | Triple Negative Locally Advanced Non-resectable Breast Cancer

Czech Republic, Italy, Poland, Spain, Austria, France, Greece
The University of New South Wales
National Health and Medical Research Council, Australia; Novo Nordisk A/S; Sydney...

Completed

Rosiglitazone and Insulin in T1DM Adolescents

Type 1 Diabetes | Puberty: >Tanner 2 Breast Development or Testis >4ml

Australia
Medical University Innsbruck

Unknown

Ropivacaine 0,2% Plus Dexamethasone Versus Ropivacaine 0,2% Plus Placebo in Modified Pectoral Block

Anesthesia, Local | Effect of Drugs | Breast Pain

Austria
Ambrx, Inc.

Recruiting

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

HER2 Positive Metastatic Breast Cancer

United States, Korea, Republic of, France, Australia
Hoffmann-La Roche

Terminated

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer (IPATunity150)

Breast Cancer

United States, Brazil, Australia, Canada, Japan, Korea, Republic of, Spain, United Kingdom
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy (KATE2)

Metastatic Breast Cancer

United States, Korea, Republic of, United Kingdom, Germany, Spain, Taiwan, Australia, Canada, Italy

Clinical Trials on Mammographic Breast Density in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations